A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
for
Relapsed or Refractory Multiple Myeloma
Location: Duarte CA
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07681596
Phase1, Phase2, Recruiting
Active & ResponsiveNew
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: La Crosse WI
Sponsor: PrECOG, LLC.
Sex: All
Age: 18 - 70+
Code: NCT07285239
Phase3, Recruiting
Active & Responsive
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: Omaha NE, West Hollywood CA
Sponsor: Oncotherapeutics
Sex: All
Age: 0+
Code: NCT06115135
Phase2, Recruiting
Active & Responsive
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
for
Multiple Myeloma
Location: St. John's, Halifax, Montreal, Toronto, London,
Sponsor: Canadian Myeloma Research Group
Sex: All
Age: 65+
Code: NCT05272826
Phase2, Recruiting
Active & Responsive
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
for
Multiple System Atrophy, Parkinsons Disease
Location: Lexington KY
Sponsor: Craig van Horne, MD, PhD
Sex: All
Age: 40 - 70+
Code: NCT06683365
Phase1, Recruiting
Active & Responsive
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
for
Multiple Myeloma (MM)
Location: Maywood IL, Milwaukee WI
Sponsor: Medical College of Wisconsin
Sex: All
Age: 18+
Code: NCT07236502
Recruiting
Active & Responsive
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, New York NY, Montreal, Winston-Salem NC,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07391657
Phase3, Recruiting
Active & Responsive
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07075185
Phase1, Recruiting
Active & Responsive
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma